Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
J&J to buy psychiatric drug developer Intra-Cellular Therapies for $14.6 billion, adding schizophrenia drug CAPLYTA at a 39% premium on the companys closing…
Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers' reentry into neuroscience…
J&J Q1 2026 results (released 2026-04-14): Caplyta (lumateperone) reported worldwide net sales of $270M for the quarter, all U.S. CAPLYTA continued to build…
Source summaries from our enrichment pipeline; follow links for originals.
All 18 sources with sentiment breakdown →
J&J acquired Intra-Cellular Therapies for $14.6B for neurological drugs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Intra-Cellular Therapies (this deal) | 2025 | $14.6B | 76 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2025 deals · Johnson & Johnson deals · Neurology deals